Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...
PARTNER 3 may notch a win for transcatheter aortic valve replacement in patients with low surgical risk, according to experts ...
No one was more surprised than Dr. Rick Dearman when he was diagnosed with severe symptomatic aortic stenosis, also known as heart valve failure. As a heart surgeon, he’d treated hundreds of people ...
Investor's Business Daily on MSN
The 'Halo Effect' Bolstering Edwards Lifesciences' Biggest Moneymaker
Edwards Lifesciences stock fell Friday, though the medtech company boosted its 2025 outlook after beating quarterly calls.
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback